BMC
IMNM icon

Bear Mountain Capital’s Immunome IMNM Stock Holding History

Bear Mountain Capital’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$485 Hold
20
– – ﹤0.01% 154
2025
Q4 		$457 Hold
20
– – ﹤0.01% 156
2025
Q3 		$335 Hold
20
– – ﹤0.01% 230
2025
Q2 		$212 Hold
20
– – ﹤0.01% 165
2025
Q1 		$171 Hold
20
– – ﹤0.01% 322
2024
Q4 		$204 Buy
+20
New +$242 ﹤0.01% 161

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Bear Mountain Capital's IMNM Position: Q1 2026 in Review

Bear Mountain Capital held its Immunome (IMNM) position steady in Q1 2026 at 20 shares worth $485. The position accounts for ﹤0.01% of the portfolio, ranked #154.

Bear Mountain Capital first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Bear Mountain Capital held 20 shares of Immunome worth $485 as of Q1 2026.
  • Bear Mountain Capital left its Immunome share count unchanged in Q1 2026.
  • Immunome made up ﹤0.01% of Bear Mountain Capital's portfolio in Q1 2026, its #154 holding.
  • Bear Mountain Capital first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Bear Mountain Capital's 13F filing for Q1 2026, filed 12 May 2026.